MODUS THERAPEUTICS

modus-therapeutics-logo

Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.

#SimilarOrganizations #People #Financial #Website #More

MODUS THERAPEUTICS

Social Links:

Industry:
Biotechnology Clinical Trials Pharmaceutical Therapeutics

Founded:
2011-01-01

Address:
Stockholm, Stockholms Lan, Sweden

Country:
Sweden

Website Url:
http://www.modustx.com

Total Employee:
1+

Status:
Active

Contact:
556669-2199

Email Addresses:
[email protected]

Total Funding:
183.5 M SEK

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Nginx Microsoft Exchange Online Office 365 Mail Google Maps


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.


Current Advisors List

tomas-odergren_image

Tomas Odergren Board Member @ Modus Therapeutics
Board_member

mats-wahlgren_image

Mats Wahlgren Board Member @ Modus Therapeutics
Board_member

björn-sjöstrand_image

Björn Sjöstrand Chairman @ Modus Therapeutics
Board_member

torsten-goesch_image

Torsten Goesch Board Member @ Modus Therapeutics
Board_member

Current Employees Featured

ellen-wittmack-donnelly_image

Ellen Wittmack Donnelly
Ellen Wittmack Donnelly CEO @ Modus Therapeutics
CEO
2017-04-01

mats-wahlgren_image

Mats Wahlgren
Mats Wahlgren Co-Founder, Chief Scientific Officer @ Modus Therapeutics
Co-Founder, Chief Scientific Officer

thomas-knittel_image

Thomas Knittel
Thomas Knittel Chief Medical Officer @ Modus Therapeutics
Chief Medical Officer

lena-jendeberg_image

Lena Jendeberg
Lena Jendeberg Vice President, Development @ Modus Therapeutics
Vice President, Development

Founder


mats-wahlgren_image

Mats Wahlgren

Stock Details


Company's stock symbol is STO:MODTX

Investors List

karolinska_image

Karolinska

Karolinska investment in Post-IPO Debt - Modus Therapeutics

healthcap_image

HealthCap

HealthCap investment in Series A - Modus Therapeutics

rosetta-capital_image

Rosetta Capital

Rosetta Capital investment in Venture Round - Modus Therapeutics

praktikerinvest_image

Praktikerinvest

Praktikerinvest investment in Venture Round - Modus Therapeutics

kdev-investments_image

KDev Investments

KDev Investments investment in Venture Round - Modus Therapeutics

ostersjostiftelsen_image

Ostersjöstiftelsen

Ostersjöstiftelsen investment in Venture Round - Modus Therapeutics

Official Site Inspections

http://www.modustx.com Semrush global rank: 8.3 M Semrush visits lastest month: 335

  • Host name: 77.68.2.47
  • IP address: 77.68.2.47
  • Location: United Kingdom
  • Latitude: 51.4964
  • Longitude: -0.1224
  • Timezone: Europe/London

Loading ...

More informations about "Modus Therapeutics"

Modus Therapeutics - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number 556669-2199 Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people …See details»

About us - Modus Therapeutics

Born: 1965 Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 18 years’ experience from venture capital in life sciences. Drvota was responsible for life science at SEB Venture …See details»

Invitation to subscribe for units in Modus Therapeutics Holding AB

Format via the Company's website, www.modustx.com, or be obtained by the Company in paper format at Modus' office with address: Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden. The …See details»

Modus Therapeutics Holding AB - LinkedIn

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s near-term focus is to develop sevuparin for patients with …See details»

Modus Therapeutics

Dec 5, 2024 The company was founded in 2013 by a small group of scientists and doctors in Stockholm, Sweden. The mission of Modus Therapeutics is to develop innovative treatments …See details»

MODTX Company Description - Stock Analysis

Dec 10, 2024 Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide …See details»

Annual Report 2021 - modustx.com

Contract manufacturing organization, has started manufacturing sevuparin drug product securing the supply for the Phase II clinical development. This follows a drug supply agreement …See details»

Annual General Meeting in Modus Therapeutics Holding AB (publ) …

Email: [email protected] . Certified Adviser . Svensk Kapitalmarknadsgranskning AB . Phone: +46 11 32 30 732 . Email: [email protected] *** About Modus Therapeutics and sevuparin . …See details»

Modus Therapeutics Holding AB, MODTX:STO profile - FT.com

Modus Therapeutics Holding AB (MODTX:STO) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»

Modus Therapeutics - VentureRadar

Similar Companies: Imara USA Privately Held Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients …See details»

INTERIM REPORT - modustx.com

“Subsidiary” or “Modus Therapeutics” refers to the subsidiary Modus Therapeutics AB with organization number 556669–2199. The third quarter in figures • The loss after tax amounted …See details»

Modus Therapeutics Holding AB (publ) publishes annual report for …

Apr 11, 2024 More information is available at www.modustx.com. Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including …See details»

Modus Therapeutics - Symbiosis Pharmaceutical Services Starts …

Oct 18, 2021 Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis …See details»

Modus Therapeutics Announces the Results of its Global

STOCKHOLM, SWEDEN – 13 May 2019: Modus Therapeutics AB announces the initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the …See details»

Modus Therapeutics Holding AB (publ) (MODTX.ST) - Yahoo Finance

Find the latest Modus Therapeutics Holding AB (publ) (MODTX.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

INTERIM REPORT JANUARY – MARCH 2021 - modustx.com

“The Company” or “Modus” refers to the parent company Modus Therapeutics Holding AB with organization number 556951– 9523. “Subsidiary” or “Modus Therapeutics” refers to the …See details»

MODTX Stock Price and Chart — OMXSTO:MODTX - TradingView

Modustx.com. Headquarters. Stockholm. Founded. 2011. ISIN. SE0015987904. FIGI. BBG011KFL2X6. Modus Therapeutics Holding AB operates as a biotechnology company. It …See details»

Press release - Modus Therapeutics

The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report. John Öhd, Modus …See details»

MODTX Stock Price Quote | Morningstar

Dec 11, 2024 See the latest Modus Therapeutics Holding AB stock price (MODTX:XSTO), related news, valuation, dividends and more to help you make your investing decisions.See details»

Press release - Modus Therapeutics

More information is available at www.modustx.com. Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including …See details»

linkstock.net © 2022. All rights reserved